NCCN-Lilly RFP on quality of care in gastric cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The National Comprehensive Cancer Network announced a collaboration with Eli Lilly and Co. to offer a new opportunity seeking proposals to bridge gaps in care for gastric and gastroesophageal junction cancer patients in the U.S. The Request for Proposals outlines the scope and process that will be followed for the submission of Letters of Intent.

The intent of the RFP is to encourage U.S. organizations to submit LOIs describing concepts and ideas for developing, implementing, and evaluating programs that close clinical practice gaps and improve the quality of care for patients with gastric/GEJ cancer through adherence to evidence-based medicine guidelines, and improved competence and performance of health care providers and health care systems.

NCCN views this collaboration with Lilly as clear recognition of the advantages offered to industry and organizations treating cancer patients through the NCCN Oncology Research Program.

LOIs are due by 11:59 PM EDT, Wednesday, Oct. 24. Please direct questions in writing to Nicole Kamienski at kamienski@nccn.org with the subject line, “2018 Gastric Project.”

YOU MAY BE INTERESTED IN

Just consider for a minute if this was the first year of running your lab, if you were on the job market as a physician or scientist right now, if you were a resident contemplating a career in cancer research after fellowship, if you were a graduate student or postdoc, if you were an undergraduate or a technician who was looking toward graduate school.
The immune system can be a powerful tool to control cancer. Immune cells within our body detect cancer cells and release payloads that kill them. Transformative science in the last decade has led to the development of therapies that enhance the ability of our immune cells to carry out this function. These therapies, including checkpoint blockade and CAR-T cells, have been lifesaving for many patients that before had untreatable cancer. But, sadly, a majority of patients with advanced solid tumors still succumb to their disease. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login